Oxymorphone

DRUG5 trials

Sponsors

Icahn School of Medicine at Mount Sinai, Sandoz, Roxane Laboratories, Vanderbilt University, M.D. Anderson Cancer Center

Conditions

Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmMetastatic Malignant Solid NeoplasmPainPostoperative Nausea and Vomiting

Early Phase 1

Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer

TerminatedNCT03579446

M.D. Anderson Cancer CenterHematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm

Start: 2018-11-29End: 2023-06-15Updated: 2025-08-03

Phase 1

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

CompletedNCT00857428

Start: 2007-11-30End: 2007-12-31Updated: 2017-03-29

Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions

CompletedNCT00857428

Start: 2007-11-30End: 2007-12-31Updated: 2017-03-29

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

CompletedNCT01210638

Roxane LaboratoriesPain

Start: 2008-06-30End: 2008-06-30Updated: 2018-01-23

Unknown Phase

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

CompletedNCT00580294

Icahn School of Medicine at Mount SinaiPain

Start: 2007-11-30End: 2008-08-31Updated: 2016-02-03

Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis

CompletedNCT02625181

Vanderbilt UniversityPostoperative Nausea and Vomiting

Start: 2016-07-31End: 2017-11-30Updated: 2019-03-07